DSGN Key Statistics, Chart & Performance
The current stock price of DSGN is 9.1 USD. In the past month the price decreased by -6.86%. In the past year, price increased by 36.64%.
DSGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About DSGN
Company Profile
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. The company is headquartered in Carlsbad, California and currently employs 55 full-time employees. The company went IPO on 2021-03-26. The company is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Company Info
DESIGN THERAPEUTICS INC
6005 Hidden Valley Road, Suite 110
Carlsbad CALIFORNIA 92011 US
CEO: Joao Siffert
Employees: 55
Phone: 18582934900
DESIGN THERAPEUTICS INC / DSGN FAQ
What does DESIGN THERAPEUTICS INC do?
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. The company is headquartered in Carlsbad, California and currently employs 55 full-time employees. The company went IPO on 2021-03-26. The company is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Can you provide the latest stock price for DESIGN THERAPEUTICS INC?
The current stock price of DSGN is 9.1 USD. The price decreased by -2.99% in the last trading session.
Does DESIGN THERAPEUTICS INC pay dividends?
DSGN does not pay a dividend.
How is the ChartMill rating for DESIGN THERAPEUTICS INC?
DSGN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting DSGN stock to perform?
9 analysts have analysed DSGN and the average price target is 11.99 USD. This implies a price increase of 31.7% is expected in the next year compared to the current price of 9.1.
What is the employee count for DSGN stock?
DESIGN THERAPEUTICS INC (DSGN) currently has 55 employees.
DSGN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to DSGN. When comparing the yearly performance of all stocks, DSGN is one of the better performing stocks in the market, outperforming 92.91% of all stocks.
DSGN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DSGN. No worries on liquidiy or solvency for DSGN as it has an excellent financial health rating, but there are worries on the profitability.
DSGN Financial Highlights
Over the last trailing twelve months DSGN reported a non-GAAP Earnings per Share(EPS) of -1.19. The EPS decreased by -40% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.85% | ||
| ROE | -33.77% | ||
| Debt/Equity | 0 |
DSGN Forecast & Estimates
9 analysts have analysed DSGN and the average price target is 11.99 USD. This implies a price increase of 31.7% is expected in the next year compared to the current price of 9.1.